“If we don’t get EAU, then all is lost IMO.”

“If we don’t get EAU, then all is lost IMO.”

This statement is a bit over the top. The mild to moderate population isn’t really the COVID19 population we worry about. We worry more for the mod-severe and severe-critical. Yes, mild/moderate can progress to hospitalization and death, but our 84 person M2M trial demonstrated that few do with or without treatment. The severe trial is slowly enrolling, but the interim analysis will big the bigger and more important news.

My point is this: The M2M data is important but it’s not a game changer. Yes, there’s an unmet need and leronlimab can improves ones health faster, etc., but the need is for hospitalization, ventilation, and death. Remdesevir was given EUA because it decreased hospital stay in patients on low flow oxygen. Basically, no EUA for M2M isn’t going to change much and I believe that a no on the EUA is already factored into the SP as the market didn’t respond to the PR with the data.